Abstracts Archive - Page 862 of 2425 - ACR Meeting Abstracts

Abstract Number: 1554 • 2019 ACR/ARP Annual Meeting
Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study
Philip Mease¹, Robert B.M. Landewé ², Proton Rahman ³, Hasan Tahir ⁴, Atul Singhal ⁵, Elke Böttcher ⁶, Sandra Navarra ⁷, Aimee Readie ⁸, Shephard Mpofu ⁹, Evie Maria Delicha ⁹, Luminita Pricop ⁸ and Désirée van der Heijde ¹⁰, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁵Southwest Rheumatology, Dallas, TX, ⁶Rheumazentrum Favoriten, Vienna, Austria, ⁷University of Santo Tomas Hospital, Manila, Philippines, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Secukinumab (SEC) provided sustained efficacy, inhibition of radiographic progression, and stable safety profile over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA)…
Abstract Number: 1555 • 2019 ACR/ARP Annual Meeting
Drug Survival and Safety of Biosimilar CT-P13 versus Reference Infliximab in Patients with Ankylosing Spondylitis: Data from the Korean College of Rheumatology Biologics Registry
Hyoun-Ah Kim¹, Eunyoung Lee ¹, Sun Kyung Lee ², Yong-Beom Park ³ and Kichul Shin ⁴, ¹Ajou University School of Medicine, Suwon, Republic of Korea, ²Seoul Metropolitan Government-Seoul National University Hospital Boramae Medical Center, Seoul, Republic of Korea, ³Yonsei university college of medicine, severance hospital, Seodaemun-gu, Seoul-t'ukpyolsi, Republic of Korea, ⁴Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea., seoul, Republic of Korea
Background/Purpose: CT-P13 is the first biosimilar of the reference infliximab (IFX) prescribed for rheumatoid arthritis, ankylosing spondylitis (AS), Crohn's disease, ulcerative colitis, psoriasis, and psoriatic…
Abstract Number: 1556 • 2019 ACR/ARP Annual Meeting
Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms
Jun Shen¹, Anjaneya Chimalakonda ¹, Miroslawa Nowak ¹, John Throup ¹, Subhashis Banerjee ¹ and Ihab Girgis ¹, ¹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986165 is an oral, selective inhibitor of TYK2, an enzyme that activates signal transducer and activator of transcription (STAT)-dependent cytokine signaling pathways, including the…
Abstract Number: 1557 • 2019 ACR/ARP Annual Meeting
Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Daniela DiGuiseppe ², Anne Gitte Loft ³, Manuel Pombo-Suarez ⁴, Herman Mann ⁵, Ziga Rotar ⁶, Florenzo Iannone ⁷, Tore Kvien ⁸, Maria José Santos ⁹, Kari K. Eklund ¹⁰, Bjorn Gudbjornsson ¹¹, Catalin Codreanu ¹², Sema Yılmaz ¹³, Johan Askling ¹⁴, Carlos Sánchez-Piedra ¹⁵, Karel Pavelka ⁵, Matija Tomsic ¹⁶, Fabrizio Conti ¹⁷, Joe Sexton ¹⁸, Helena Santos ¹⁹, Nina Trokovic ²⁰, Thorvardur J Love ²¹, Ruxandra IONESCU ²², Yavuz Pehlivan ²³, Michael J. Nissen ²⁴, Gary Macfarlane ²⁵, Irene van der Horst-Bruinsma ²⁶, Stylianos Georgiadis ²⁷, Lykke Midtbøll Ørnbjerg ²⁸, Cecilie Heegaard Brahe ²⁸, Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁴Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ⁷Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁸Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹¹Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ¹⁴Karolinska Institutet, Stockholm, Sweden, ¹⁵Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁶Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ¹⁷Sapienza University of Rome, Rome, Italy, ¹⁸Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁹Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ²⁰Helsinki University Central Hospital, Helsinki, Finland, ²¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²²SPITALUL CLINIC SFANTA MARIA, Bucharest, ²³Uludağ University, Bursa, Turkey, ²⁴University Hospital Geneva, Geneva, Switzerland, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁷DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Secukinumab represents a relatively new approach to treating patients with psoriatic arthritis (PsA) and has shown promising results in RCTs. However, there is a…
Abstract Number: 1558 • 2019 ACR/ARP Annual Meeting
Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?
Whitney Bembry¹, Dasha Lopez ², Christopher Mesa ³, Nirupa Patel ³ and Myriam Guevara ⁴, ¹Tulane University School of Medicine, New Orleans, LA, ²Baton Rouge General Hospital, Baton Rouge, LA, ³Louisiana State University School of Medicine, New Orleans, LA, ⁴Louisiana State University School of Medicine, New Orleans
Background/Purpose: Evidence of podocyte effacement on electron microscopy and significant proteinuria in a systemic lupus erythematosus (SLE) patient with biopsy proven minimal mesangial (MM), mesangial…
Abstract Number: 1559 • 2019 ACR/ARP Annual Meeting
Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE
Eric Morand¹, Kevin Zhang ¹, Sarah Boyd ¹, Francois Petitjean ¹, Alberta Hoi ², Rachel Koelmeyer ¹ and Hieu Nim ¹, ¹Monash University, Melbourne, Victoria, Australia, ²School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia
Background/Purpose: Prevention of permanent organ damage, a major predictor of morbidity and mortality, is a key goal in the treatment of SLE. Physician-measured disease activity…
Abstract Number: 1560 • 2019 ACR/ARP Annual Meeting
Imbalance Between Th17 and Regulatory T Cells in Patients with Systemic Lupus Erythematosus Combined EBV/CMV Viremia
Rui Su¹, Yue Liu ¹, Xinyu Zheng ¹, Xiao-feng Li ² and Cai-hong Wang ³, ¹Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan , Shanxi, China, Tai Yuan, China (People's Republic), ²Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan , Shanxi, China, TaiYuan, China (People's Republic), ³The Second Hospital of Shanxi Medical University, Tai Yuan, China (People's Republic)
Background/Purpose: Infection is common and is one of the leading causes of morbidity and mortality in Systemic Lupus Erythematosus (SLE) patients . Excessive using glucocorticoid…
Abstract Number: 1561 • 2019 ACR/ARP Annual Meeting
Decreased Nocturnal Blood Pressure Dipping in Patients with Systemic Lupus Erythematosus: Association with Markers of Inflammation
Daniel Carranza Leon¹, Annette Oeser ¹, Qiong Wu ¹, C. Michael Stein ², Michelle Ormseth ¹ and Cecilia Chung ², ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Blood pressure follows a circadian rhythm; usually systolic blood pressure (SBP) drops by more than 10% during the night. Absence of this phenomenon, known…
Abstract Number: 1562 • 2019 ACR/ARP Annual Meeting
The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus
Sarah Bayefsky¹, Alyson Dickson ¹, Tyler Reese ¹, Jocelyn Gandelman ², Megan Shuey ¹, April Barnado ¹, Katherine Barker ¹, C. Michael Stein ¹, Vivian Kawai ¹ and Cecilia Chung ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University School of Medicine, Nashville, TN
Background/Purpose: Recent studies have suggested that body weight fluctuation in the general population is an independent risk factor for overall mortality. These findings are of…
Abstract Number: 1563 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?
Muhsen Al-ani¹, Bobby Kwanghoon Han ² and Gregory c Gardner ³, ¹University of Washington, seattle, WA, ²University of Washington, seattle, ³University of Wasshington, seattle
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease with a variety of clinical manifestations but interestingly interstitial lung disease (ILD) is rare. The literature to…
Abstract Number: 1564 • 2019 ACR/ARP Annual Meeting
Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis
Shivani Garg¹, Sarah Panzer ², Karen Hansen ³, Callie Plafkin ⁴, Maureen Smith ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW-Madison, Madison, ³UW Madison, Madison, ⁴UW Health, Madison
Background/Purpose: Patients with lupus nephritis (LN) have a 9-fold higher risk of cardiovascular disease (CVD), highlighting the urgent need to target CVD prevention. Studies in…
Abstract Number: 1565 • 2019 ACR/ARP Annual Meeting
Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus
Jagan Sivakumaran¹, Paula Harvey ², Ahmed Omar ³, Murray Urowitz ³, Dafna Gladman ⁴, Nicole Anderson ³, Jiandong Su ³ and Zahi Touma ³, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is recognized as an independent risk factor for cardiovascular disease (CVD). This study aimed to determine which cardiovascular risk assessment…
Abstract Number: 1566 • 2019 ACR/ARP Annual Meeting
HER2 as a Biomarker of Proliferative Lupus Nephritis in Children
Kathleen Sullivan¹, Jonathan Burnham ², Kathleen O'Neil ³, Laura Schanberg ⁴, Emily von Scheven ⁵, Marisa Klein-Gitelman ⁶ and Patricia Costa Reis ⁷, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Indiana University, Indianapolis, IN, ⁴Duke University Medical Center, Durham, NC, ⁵UCSF, San Francisco, CA, ⁶Lurie Children's Hospital, Chicago, IL, ⁷Hospital de Santa Maria, Lisbon, Portugal
Background/Purpose: Lupus nephritis is a common feature of SLE and confers a poor prognosis. 20-50% of patients with lupus nephritis ultimately develop chronic kidney disease…
Abstract Number: 1567 • 2019 ACR/ARP Annual Meeting
Cachexia in Systemic Lupus Erythematosus
George Stojan¹, Jessica Li ² and Michelle Petri ², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cachexia is a syndrome that may accompany a range of diseases, including cancer, chronic heart failure, chronic obstructive pulmonary disease, and rheumatoid arthritis. It…
Abstract Number: 1568 • 2019 ACR/ARP Annual Meeting
High Risk Low Attenuation Non-Calcified Coronary Plaque in Lupus vs. Controls
George Stojan¹, Jessica Li ² and Michelle Petri ², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The presence of low attenuation noncalcified plaque (< 30 Haunsfield units) is one of the most characteristic vessel changes in unstable coronary plaques. Low-attenuation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].